These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 12823117)

  • 1. Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis.
    Jahnz-Rózyk K; Targowski T; Głodzinska-Wyszogrodzka E; Płusa T
    Allergy; 2003 Jul; 58(7):595-601. PubMed ID: 12823117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
    Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
    J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
    Kuehr J; Brauburger J; Zielen S; Schauer U; Kamin W; Von Berg A; Leupold W; Bergmann KC; Rolinck-Werninghaus C; Gräve M; Hultsch T; Wahn U
    J Allergy Clin Immunol; 2002 Feb; 109(2):274-80. PubMed ID: 11842297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE; Monasterolo G
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pre-seasonal birch/hazel sublingual immunotherapy can improve the outcome of grass pollen injective treatment in bisensitized individuals. A case-referent, two-year controlled study.
    Cirla AM; Cirla PE; Parmiani S; Pecora S
    Allergol Immunopathol (Madr); 2003; 31(1):31-43. PubMed ID: 12573207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
    Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
    J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of nasal immunohistology in patients with seasonal rhinoconjunctivitis treated with topical steroids or specific allergen immunotherapy.
    Rak S; Heinrich C; Scheynius A
    Allergy; 2005 May; 60(5):643-9. PubMed ID: 15813810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
    Buczyłko K; van der Werf JF; Boot D; van Ree R
    Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
    Kopp MV; Brauburger J; Riedinger F; Beischer D; Ihorst G; Kamin W; Zielen S; Bez ; Friedrichs F; Von Berg A; Gerhold K; Hamelmann E; Hultsch ; Kuehr J
    J Allergy Clin Immunol; 2002 Nov; 110(5):728-35. PubMed ID: 12417881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of allergen immunotherapy and drug treatment in seasonal rhinoconjunctivitis: a 3-years study.
    Giovannini M; Braccioni F; Sella G; Contoli M; Perri G; Frati F; Incorvaia C
    Eur Ann Allergy Clin Immunol; 2005 Feb; 37(2):69-71. PubMed ID: 15859367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
    Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
    J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of specific immunotherapy on serum eotaxin level in patients with pollinosis: preliminary studies].
    Jahnz-Rózyk K; Głodzińska-Wyszogrodzka E; Rozyńska-Polańska R; Paluchowska E; Zabielski LS
    Pol Merkur Lekarski; 2001 Sep; 11(63):244-6. PubMed ID: 11761820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of age and gender on serum eotaxin concentration in healthy and allergic people.
    Targowski T; Jahnz-Rózyk K; Plusa T; Glodzinska-Wyszogrodzka E
    J Investig Allergol Clin Immunol; 2005; 15(4):277-82. PubMed ID: 16433209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
    Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
    Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relevance of patient-reported outcomes in a grass pollen immunotherapy trial in children and adolescents with rhinoconjunctivitis.
    Röder E; Berger MY; Hop WC; de Groot H; van Wijk RG
    Pediatr Allergy Immunol; 2013 Feb; 24(1):39-48. PubMed ID: 22882319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
    Winther L; Malling HJ; Mosbech H
    Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.